Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Anticancer drugs: How to select small molecule combinations?
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 503-519
Closed Access | Times Cited: 13
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Anupriya Singhal, Hannah C. Styers, Jonathan Rub, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2122-2134
Closed Access | Times Cited: 9
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Discovery of fully synthetic FKBP12-mTOR molecular glues
Robin C. E. Deutscher, Christian Meyners, Maximilian Repity, et al.
Chemical Science (2025) Vol. 16, Iss. 10, pp. 4256-4263
Open Access | Times Cited: 1
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer
Olaf Klingbeil, Damianos Skopelitis, Claudia Tonelli, et al.
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2471-2488
Open Access | Times Cited: 5
Regulating MYC translation in cancer
Zainab Hussain, Mara H. Sherman
Nature Cell Biology (2025)
Closed Access
Insights into curcumin’s anticancer activity in pancreatic ductal adenocarcinoma: Experimental and computational evidence targeting HRAS, CCND1, EGFR and AKT1
Jun‐Feng Cao, Xiao Zhang, Qingjie Xia, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108264-108264
Closed Access
Bilateral Synergistic Effects of Phototherapy‐Based NIR‐II Absorption Photosensitizer for Allergic Rhinitis
Tao Shao, Lu Han, Yang Xie, et al.
Small (2025)
Closed Access
Discovery of Novel Oxazolo[4,3-f]purine Derivatives as Antitumor Agents through PPIA Interaction
Xian-Jia Li, Meng‐Cheng Zhang, Xiang Li, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K. Mahadevan, Antonio Maldonado, Bingrui Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Multiple roles of mitochondria in tumorigenesis and treatment: from mechanistic insights to emerging therapeutic strategies
Min Zhang, Yuchen Yang, Jiacheng Wu, et al.
ONCOLOGIE (2025)
Closed Access
Evaluation of molecular glue-induced neo-Protein-Protein Interaction with a cell lysate-based TR-FRET assay
Xiulei Mo, Yuhong Du, Haian Fu
(2025), pp. 100003-100003
Open Access
Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien
Thomas Hank, Christoph Springfeld, Martin Loos, et al.
Deutsches Ärzteblatt (2025)
Closed Access
Pancreatic Cancer: Pathogenesis and Clinical Studies
Kexun Zhou, Yingping Liu, Chuanyun Tang, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Targeting the Yin and Yang of KRASG12C
Christos Adamopoulos, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
Trends in Molecular Medicine (2025)
Closed Access
Page 1 - Next Page

Scroll to top